Skip to main content
. 2020 Nov 16;20:1105. doi: 10.1186/s12885-020-07365-4

Fig. 4.

Fig. 4

Comparison of lenvatinib plasma concentration in patients with BTC (this study) to patients with DTC (Study 303) [20]. aThere were 7 patients excluded from the pharmacokinetic analysis because their dose was reduced or interrupted before cycle 1 day 15. bBodyweight-adjusted plasma concentration was calculated as follows: individual plasma concentration × bodyweight [kg]/60 [kg]. BTC, biliary tract cancer; DTC, differentiated thyroid cancer